ClinicalTrials.gg
Status unknownNCT04301921RAPID-1Updated Apr 24, 2020

Strategies to Maintain Radial Artery Patency Following Diagnostic Coronary Angiography - Diagnostic Transradial Coronary Angiography Without Systemic Anticoagulatio

An interventional study of Traditional punkcture site and No anticoagulation and Traditional punkcture site and ACT-guided anticoagulation in Patients Undergoing Diagnostic Coronary Angiography, sponsored by Prof. Dr. med. Ingo Eitel. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by Prof. Dr. med. Ingo Eitel · Not applicable, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To investigate whether omitting systemic anticoagulation during transradial coronary angiography and/or a distal radial access reduce the risk of postprocedural radial artery occlusion

02

Conditions studied

  • Patients Undergoing Diagnostic Coronary Angiography
03

In context

Lead sponsor

Prof. Dr. med. Ingo Eitel is the lead sponsor of 7 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical indication to perform diagnostic coronary angiography
  • Age > 18 years
  • Written

Exclusion criteria

Exclusion Criteria:

  • Preexisting or already administered anticoagulation prior to coronary angiography
  • Planned coronary intervention
  • Preexisting radial artery occlusion or missing pulse at the potential puncture sites
  • Allergy / intolerance to anticoagulants
  • Active bleeding or comorbidity with elevated bleeding risk
  • Pregnancy
  • Inability to sign
  • Participation in another trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Other
    Group 1

    Traditional puncture site + no anticoagulation

    Other: Traditional punkcture site and No anticoagulation

  • Other
    Group 2

    Traditional puncture site + ACT-guided anticoagulation

    Other: Traditional punkcture site and ACT-guided anticoagulation

Interventions

  • OtherTraditional punkcture site and No anticoagulation

    Traditional punkcture site and No anticoagulation

  • OtherTraditional punkcture site and ACT-guided anticoagulation

    Traditional punkcture site and ACT-guided anticoagulation

06

What researchers measure

Primary outcomes

  1. Occurrence of postprocedural RAO

    Will be the occurrence of postprocedural RAO assessed with high-resolution vascular ultrasound. Experienced sonographers will perform color Doppler ultrasound in all study patients after removal of the compression device to examine the radial, ulnar, and brachial arteries of the access forearm.

    Time frame: Day 1

  2. Bleeding events

    Will be bleeding events according to Bleeding Academic Research Consortium (BARC) criteria.

    Time frame: Day 1

Secondary outcomes

  1. Sonographic characteristics of radial artery occlusion

    Occlusion lengths or minimal residual perfusion

    Time frame: 3 Month

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2020; primary completion for Sep 2021, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2020
First posted
Mar 10, 2020
StartEst.
May 1, 2020
Primary completionEst.
Sep 30, 2021
CompletionEst.
Jun 30, 2022
Last update
Apr 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04301921
Lead sponsor
Prof. Dr. med. Ingo Eitel
Responsible party
Prof. Dr. med. Ingo Eitel (Senior physician, University of Luebeck) — Sponsor-investigator
First posted
Mar 10, 2020
Start date
May 1, 2020 (estimated)
Primary completion
Sep 30, 2021 (estimated)
Completion
Jun 30, 2022 (estimated)
Last update
Apr 24, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion